Salvage chemotherapy followed by autologous stem cell transplantation using targeted busulfan for refractory diffuse large B-cell lymphoma with dialysis-dependent end-stage renal disease

A treatment strategy of salvage chemotherapy and autologous stem cell transplantation in relapsed or refractory DLBCL patients on hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a refractory DLBCL patient with end-stage renal disease, and successfully administered adjusted dosing of salvage chemotherapies and conditioning regimen in autologous stem cell transplantation without any adverse events.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 6, 2019 Category: Hematology Authors: Kaoru Morita, Masahiro Ashizawa, Yumiko Toda, Takashi Ikeda, Shin-ichiro Kawaguchi, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fu Tags: Original Study Source Type: research